Detalles de la búsqueda
1.
Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP).
Mult Scler
; 27(3): 410-419, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32406786
2.
Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program.
Mult Scler
; 27(5): 719-728, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32579430
3.
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
J Neurol Neurosurg Psychiatry
; 91(6): 660-668, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32234967
4.
Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis.
J Pharmacokinet Pharmacodyn
; 44(3): 263-275, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28251386
5.
Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
Neurology
; 102(9): e209357, 2024 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38648580
6.
Benefits of early treatment with natalizumab: a real-world study.
Mult Scler Relat Disord
; 68: 104216, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36288658
7.
Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV® DxSelect™ antibody assay.
J Neurovirol
; 22(6): 880-881, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27730447
8.
Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every-4-Week Dosing to Extended-Interval Dosing.
J Clin Pharmacol
; 61(3): 339-348, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32949472
9.
No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP).
Ther Adv Neurol Disord
; 14: 17562864211042458, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34603507
10.
Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study.
BMJ Open
; 10(10): e038861, 2020 10 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33082194
11.
The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis.
Mult Scler Relat Disord
; 39: 101863, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31901758
12.
Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.
Neurology
; 93(15): e1452-e1462, 2019 10 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31515290
13.
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Lancet Neurol
; 17(5): 405-415, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29545067
14.
Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
Lancet Neurol
; 16(11): 925-933, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28969984
15.
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
Neurology
; 89(15): 1584-1593, 2017 Oct 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28916537
16.
Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
J Clin Endocrinol Metab
; 100(3): E487-92, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25514106
17.
A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial.
J Clin Endocrinol Metab
; 100(4): 1335-42, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25607608
18.
The risk of PML from natalizumab - Authors' reply.
Lancet Neurol
; 18(3): 230-231, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30784549
19.
Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.
J Bone Joint Surg Am
; 96(7): e52, 2014 Apr 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-24695929
20.
Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial.
J Bone Miner Res
; 28(4): 746-52, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23109251